Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 1, 2013, Pages 101-104

  Popescu, Cristina ^a,b   Popescu, Gabriel Adrian ^a,b   Arama, Victoria ^a,b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Hepatitis; Insulin resistance; Interferon alpha side effects; Type 1 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN; INSULIN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; ALPHA INTERFERON; ANTIVIRUS AGENT; AUTOANTIBODY; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE THYROIDITIS; CASE REPORT; HEPATITIS C; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LEUKOPENIA; MALE; AUTOIMMUNE DISEASE; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DRUG COMBINATION; HASHIMOTO DISEASE; HEPATITIS C, CHRONIC; IMMUNOLOGY; PANCREAS ISLET; VITILIGO; YOUNG ADULT;

ANTIVIRAL AGENTS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; HASHIMOTO DISEASE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; ISLETS OF LANGERHANS; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; VITILIGO; YOUNG ADULT;

EID: 84875427295     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review-Neth J Med 2009; 67: 376-387.
2. Masini M, Campani D, Boggi U, et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care 2005; 28: 940-941.
3. Chen LK, Chou YC, Tsai ST, Hwang SJ, Lee SD. Hepatitis C virus infection-related Type 1 diabetes mellitus. Diabet Med 2005; 22: 340-343.
4. Nakamura K, Kawasaki E, Abiru N, et al. Trajectories of anti-islet autoantibodies before development of type 1 diabetes in interferon-treated hepatitis C patients. Case reports and a literature review. Endocr J 2010; 57: 947-951.
5. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical Course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine 2002; 81:87-100.
6. Daniel AL, Houlihan JL, Blum JS, Walsh JP. Type B insulin resistance developing during interferon α therapy. Endocr Pract 2009; 15: 153-157.
7. Fujioka T, Honda M, Yoshizaki T, et al. A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-alpha plus ribavirin treatment for chronic hepatitis C. Intern Med 2010; 49: 1987-1990.
8. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alpha therapy for chronic HCV hepatitis. Lancet 1992; 14: 340: 548.
9. attovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47.
10. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291.
11. Baccala R, Kono DH, Theophilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005; 204: 9-26.
12. Lau JY Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-1009.
13. Wedemeyer H, Wiegand J, Cornberg M, Manns M. Polyethylene glycol-interferon: current status in hepatitis C virus therapy. J Gastroenterol Hepatol 2002; 17: S344-S350.
14. Uto H, Matsuoka H, Murata M, et al. A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy. Diabetes Res Clin Pract 2000; 49: 101-106.
15. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003; 18: 549-558.
16. Nakamura K, Kawasaki E, Imagawa A, et al. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care 2011; 34: 2084-2089.
17. Tanaka J, Sugimoto K, Shiraki K, et al. Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Intern Med 2008; 47: 747-749.
18. Yamazaki M, Sato A, Takeda T, Komatsu M. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C. Intern Med 2010; 49: 403-407.
19. Le May C, Chu K, Hu M, et al. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A 2006; 103: 9232-9237.
20. Watanabe J, Yamauchi T. A case of type 1 diabetes mellitus with high titer anti-GAD antibody after combined interferon and ribavirin therapy for chronic hepatitis C. Tonyobyo (Diabetes) 2007; 50: 753-757.